Premium
Adjuvant oral alkylating chemotherapy in patients with stage I epithelial ovarian cancer
Author(s) -
Gallion Holly H.,
van Nagell John R.,
Donaldson Elvis S.,
Higgins Robert V.,
Powell Deborah E.,
Kryscio Richard J.
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19890315)63:6<1070::aid-cncr2820630605>3.0.co;2-f
Subject(s) - medicine , chemotherapy , laparotomy , stage (stratigraphy) , ovarian cancer , malignancy , surgery , cancer , melphalan , oncology , paleontology , biology
From November 1973 to May 1986, 50 patients with Stage I epithelial ovarian cancer were treated at the University of Kentucky Medical Center (Lexington, KY) with oral Alkeran (melphalan) chemotherapy after primary surgery. Twenty‐two patients had Grade 1 tumors, 23 patients had Grade 2 tumors, and five patients had Grade 3 tumors. Patients with ovarian tumors of borderline malignancy were excluded from this study. Twenty‐eight patients received from six to 11 courses of chemotherapy and 22 patients completed 12 courses of chemotherapy. Chemotherapy was well tolerated and no patient died of chemotherapy‐related complications. Thirty‐eight patients underwent second‐look laparotomy and one was positive. The patient with persistent ovarian cancer at second‐look laparotomy died of disease 41 months after diagnosis and one patient died with no evidence of disease 6 months after treatment. The actuarial survival of the total group of patients was 98% at 2 years and 94% at 5 years. Fewer than 12 months of chemotherapy may be necessary to obtain long‐term survival in these patients.